Kestra Medical Technologies, Ltd.
KMTSNASDAQHealthcare● Active
$19.74
+$0.34(+1.75%)
Market Cap$1.2B
P/E Ratio—
52W High$30
52W Low$13.25
Kestra Medical Technologies, Ltd. (KMTS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KMTS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-04 | 2024-04 | 2023-04 | 2021-04 | 2020-04 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($113.81M) | ($94.12M) | ($84.24M) | ($34.10M) | ($29.47M) |
| Depreciation & Amort. | $7.97M | $11.56M | $4.86M | $0.42M | $0.48M |
| Stock-Based Comp. | $24.27M | $1.49M | $1.21M | $1.86M | $0.00M |
| Change in Working Capital | ($6.20M) | $4.39M | $1.30M | ($0.02M) | ($2.01M) |
| Net Cash from Operations | ($77.61M) | ($72.23M) | ($69.64M) | ($29.89M) | ($30.29M) |
| Investing Activities | |||||
| Capital Expenditure | ($23.59M) | ($12.51M) | ($15.46M) | ($0.34M) | ($0.23M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | ($23.31M) | ($12.23M) | ($15.46M) | ($0.33M) | ($0.23M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | ($1.65M) | ($0.80M) | ($0.67M) | ($0.19M) | ($0.18M) |
| Debt Issued / Repaid | $0.00M | $5.88M | ($5.33M) | $20.00M | $0.00M |
| Net Cash from Financing | $330.26M | $77.72M | $96.11M | $48.81M | $30.24M |
| Free Cash Flow | |||||
| Free Cash Flow | ($101.20M) | ($84.75M) | ($85.10M) | ($30.23M) | ($30.52M) |
| FCF Margin %(computed) | -169.19% | -304.70% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Kestra Medical Technologies, Ltd. data
About Kestra Medical Technologies, Ltd. (KMTS) Cash Flow Statement
Kestra Medical Technologies, Ltd. generated operating cash flow of ($0.08B) and free cash flow of ($0.10B) for 2025 — a FCF margin of -169.19%. Capital expenditure was ($0.02B).
Frequently asked questions
KMTS · 4 questionsKestra Medical Technologies, Ltd. generated free cash flow of ($0.10B) for 2025, down 19.4% year-over-year.
KMTS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10